



PHARMACEUTICAL 2022











PHARMACEUTICAL 2022



Moleculin Biotech Inc. Rank 97 of 475



The relative strengths and weaknesses of Moleculin Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moleculin Biotech Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 135% points. The greatest weakness of Moleculin Biotech Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 50%, being 326% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	72,497
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,622
Liabilities, Non-Current	63
Other Assets	11,255
Other Compr. Net Income	-24
Other Expenses	-6,564
Other Liabilities	1,412
Other Net Income	346
Property and Equipment	338
Research and Development	14,418
Revenues	0
Selling, General and Administrative Expense	8,386

Output Variable	Value in 1000 USD
Assets	84,090
Liabilities	5,097
Expenses	16,240
Stockholders Equity	78,993
Net Income	-15,894
Comprehensive Net Income	-15,906
Economic Capital Ratio	50%